Dexamethasone Aerosol In Respiratory Tract Disease

Fisch, Ben R.; Grater, William C.

doi:10.1177/009127006200200506

Cited by 9 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier studies in humans have shown that inhaled dexamethasone sodium phosphate was more effective than dry powder inhalers or MDI containing budesonide or fluticasone for cough control [4] and helped reduce the dose of systemic corticosteroids in severe asthmatics [5,6]. Improvement in the clinical status of asthmatic children was also noted following the administration of dexamethasone phosphate disodium via MDI [7,8].…”

Section: Introductionmentioning

confidence: 99%

Nebulisation of dexamethasone sodium phosphate for the treatment of severe asthmatic horses

Mainguy-Seers

Bessonnat

Picotte

et al. 2019

Equine Veterinary Journal

View full text Add to dashboard Cite

Summary Background Inhaled corticosteroids are effective in the treatment of equine asthma. A recent study reported that nebulisation of injectable dexamethasone had low systemic bioavailability in healthy horses and could represent a cost‐effective therapy for equine inflammatory lung diseases. Objectives To determine the effects of dexamethasone nebulisation on lung function in severe asthmatic horses. It was hypothesised that dexamethasone administered by nebulisation would be more effective than the same dose administered orally. Study design Randomised blinded experimental study in severe asthmatic horses. Methods Twelve severe asthmatic horses in clinical exacerbation were randomly assigned to treatment with 5 mg of dexamethasone sodium phosphate by nebulisation (n = 6) or by oral administration (n = 6), once daily for 7 days. Lung function was evaluated at baseline, after four treatment days (D4) and 24 h after the last dose (D8). The presence of residual bronchospasm was assessed on D8 with N‐butylscopolammonium bromide administration (0.3 mg/kg i.v.). A respiratory clinical score was performed daily. Serum cortisol concentration was measured at baseline, D4 and D8. Results The pulmonary elastance was unchanged in both groups while pulmonary resistance was significantly improved in the oral group on D8 (mean reduction in 1 cm H2O/L/s [CI: 0.34–1.65, P = 0.003]). All horses had residual bronchospasm at the end of the study. There was a group difference in the respiratory clinical score as it was significantly reduced in the oral group, from D5 to D8. Serum cortisol concentration decreased in all subjects. Main limitations Low number of horses and lack of placebo group. Conclusions Considering the lack of improvement of lung function and the hypothalamic‐pituitary‐adrenal axis suppression, the results of this study do not support aerosolisation of an injectable form of dexamethasone for the treatment of severe equine asthma at the dose and with the nebuliser evaluated.

show abstract

Section: Introductionmentioning

confidence: 99%

Nebulisation of dexamethasone sodium phosphate for the treatment of severe asthmatic horses

Mainguy-Seers

Bessonnat

Picotte

et al. 2019

Equine Veterinary Journal

View full text Add to dashboard Cite

show abstract

“…Early work with inhaled hydrocortisone and prednisolone powders (Brockbank and Pengelly, 1958;Herxheimer, McAllen, and Williams, 1958) and with metered aerosol (Franklin et al, 1958) showed results which seemed encouraging, but proved disappointing because of the high dosage required. Dexamethasone by aerosol in adults (Fisch and Grater, 1962;Arbesman, Bonstein, and Reisman, 1963) and in children (Siegel et al, 1964;Kravis and Lecks, Received 2 May 1973. 1966) proved to be an effective method of controlling asthma, but the drug was absorbed in amounts sufficient to give systemic effects. New interest has been aroused in this field since it has become apparent that steroids with a high index of topical activity, but relatively low adrenal suppressive action, may prove both clinically effective and systemically harmless.…”

mentioning

confidence: 99%

Betamethasone 17-valerate by aerosol in childhood asthma.

Frears¹,

Wilson²,

Friedman³

1973

Archives of Disease in Childhood

View full text Add to dashboard Cite

(1973). Archives of Disease in Childhood, 48, 856. Betamethasone 17-valerate by aerosol in childhood asthma. A double-blind cross-over trial of betamethasone 17-valerate (B17V) administered by aerosol was carried out by alternating two placebo periods with two treated periods at monthly intervals in 20 children with severe asthma. During the trial, the average of twice-daily peak expiratory flow readings was significantly increased in every child during actively treated months, compared with placebo months. Every child had fewer symptoms while using B17V, and the average reduction for the group as a whole was 71 %. Very much less additional medication for asthma was required during months of active treatment. The observed clinical response to therapy was dramatic in over half the children. No side effects were noted. Under the conditions of this study, we conclude that B17V by aerosol appears to be safe, and is effective for the control of asthma in children.

show abstract

“…Use of dexamethasone and its esters proved to be therapeutically effective [2,4,6,7,11,26,32], However, these esters, too, caused side-effects [32].…”

mentioning

confidence: 99%

Functional Evaluation of a Corticosteroid Molecule Activity, Dexamethasone-Isonicotinate, by Aerosol Dosage in Obstructive Lung Disease

Scotti¹,

Aresini²

1975

Respiration

View full text Add to dashboard Cite

The authors experimented with a corticosteroid molecule, dexamethasone-isonicotinate, by pressurized aerosol, testing it on 15 subjects suffering from a bronchial obstructive syndrome (7 cases of asthmatic bronchitis, 6 of chronic bronchitis with pulmonary emphysema, 2 of bronchial asthma). In such patients clinical evolution, spirographic patterns, and airway resistance were studied by means of body plethysmograph before and after administration of 0.25 mg dexamethasone-isonicotinate four times a day. In four subjects daily variations of airway resistance before and after 10 days of treatment were evaluated: in three cases the resistance diminished noticeably at all times of the day after therapy. In eleven cases the functional parameters were recorded before and after 7 days therapy, and ten subjects were followed up by a monthly, check during 6 months of therapy. In both methods, the authors obtained good or very good results in more than half of the subjects and fair results in a fifth of the subjects; in the remaining patients poor results were obtained. Side-effects attributed to improper dosage were never observed.

show abstract

Dexamethasone Aerosol In Respiratory Tract Disease

Cited by 9 publications

References 8 publications

Nebulisation of dexamethasone sodium phosphate for the treatment of severe asthmatic horses

Nebulisation of dexamethasone sodium phosphate for the treatment of severe asthmatic horses

Betamethasone 17-valerate by aerosol in childhood asthma.

Functional Evaluation of a Corticosteroid Molecule Activity, Dexamethasone-Isonicotinate, by Aerosol Dosage in Obstructive Lung Disease

Contact Info

Product

Resources

About